In tumour xenograft experiments, treatment regimens are administered and the tumour volume of each individual is measured repeatedly over time. Survival data are recorded due to the death of some individuals during the observation time period. Also, cure data are observed due to a portion of individuals who are completely cured in the experiments. When modelling these data, certain constraints have to be imposed on the parameters in the models to account for the intrinsic growth of the tumour in the absence of treatment. Also, the likely inherent association of longitudinal and survival-cure data has to be taken into account in order to obtain unbiased estimators of parameters. In this paper, we propose such models for the joint mod-
Introduction
In cancer drug development, demonstrating anti-tumor activity in an in vivo experiment is an important and necessary step to make a promising experimental treatment available to humans. The xenograft model is a commonly used in vivo model in cancer research, for which severe combined immunodeficient (scid) mice are grafted with human cancer cells after which they receive a treatment and are then followed up. [1] presented a typical xenograft experiment, where several treatment regimens are administered and an outcome variable, tumour volume, is measured at the start of the treatment and then at regular follow-up times. In the literature, methodology has been developed to analyze repeated measurements and survival times collected from xenograft experiments. For example, [2] developed a t-test via the EM algorithm and also a Bayesian approach for testing for differences in effects between two treatment regimens. If no treatment were given to the tumour-bearing mice, the tumours would keep growing until the mice died or are sacrificed. Therefore, certain constraints have to be imposed on the parameters in the model to account for the intrinsic growth of a tumour in the absence of treatment. [1] considered a class of regression models for longitudinal outcomes with constrained parameters. [3] proposed a Bayesian hierarchical model to account for the parameter constraints. However, these authors ignored the very likely inherent association between longitudinal responses and survival outcomes for data coming from the same subject. As a result, such statistical inferences may be biased.
Joint models for both longitudinal and survival data have been developed in recent years and are extensively reviewed by [4] . It is well known nowadays that analyzing combined longitudinal data and survival data can lead to a significant improvement in the efficiency of statistical modelling compared to the separate analyses -see, for example, [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] and [13] . When there are cured individuals in the survival studies, either due to immunes or long-term survivors, joint models for survival and cured data have been considered by [14] , [15] , [16] and [17] . Longitudinal and survival-cure models have been further developed by [18] , [19] and [20] .
The mixture distribution for the longitudinal model in [18] is very unique which is not suitable to our study. [19] and [20] studied a prostate cancer data, where longitudinal data have an inherent relationship with survival outcomes and survival hazard rate are modelled separately for cured patients and uncured patients. However, these models are not suitable for analyzing the tumour data arising in xenograft experiments for the following reason. This is because these models assume the cure probability only depends on the baseline covariates, rather than being related with other characteristics of the longitudinal measurements. This assumption may not be true in xenograft experiments because the cure probability of a mouse will clearly be related not only to the baseline tumor size but also to how fast the tumor grows or other characteristics of tumor volumes.
In this paper, motivated by a dataset from an xenograft experiment for mice, we propose new joint models for longitudinal and survival-cure data by taking into account not only the likely inherent association of the different types of data but also the intrinsic growth of a tumour in the absence of any treatment [21] . The random effects in linear mixed models for longitudinal data, after being properly scaled, are incorporated into the Cox hazard model for survival data and the logistic model for cure data, so that the inherent association between the different types of data can be accounted for. The fixed effects in the longitudinal linear mixed models, on the other hand, are imposed constraints in order to account for the intrinsic growth of a tumour in the absence of treatment. Posterior inferences for the parameters in the models are obtained by using a Markov chain Monte Carlo (MCMC) method.
The rest of the paper is organized as follows. In Section 2, we define the joint longitudinal and survival-cure models for the xenograft experimental data and provide the log-likelihood function for the complete data. In Section 3, we specify prior distributions for the parameters and provide model selection criteria for finding the best model. In Section 4, we use a MCMC method to generate random samples from the posterior distributions of the parameters and apply to the real xenograft data analysis involving two new anticancer agents against rhabdomyosarcomas. In Section 5 we carry out simulation studies to access the performance of the proposed approach. Numerical results show that the proposed joint modelling strategy outperforms the separate modelling methods. Further comments and discussions are given in Section 6.
Data and Models

Data set
The xenograft experimental data in [1] and [22] are about two new anticancer agents: temozolomide (TMZ) and irinotecan (CPT-11). TMZ is a methylating agent that has been approved for treatment of astrocytoma and is entering various phases of clinical evaluation against tumours. CPT-11 has demonstrated a broad activity against both murine and human tumour xenograft models and clinically significant activity against many types of cancer. A DNA analysis has formed the biochemical rationale for combining TMZ and CPT-11. Our primary objective is to analyze the activity of TMZ combined with CPT-11 against one rhabdomyosarcoma (Rh18) xenograft. Mice from the same strain were used and they are virtually genetically identical.
In total, we have 51 subjects (mice) observed, which are divided into eight groups for different treatment regimens. Two dose levels were considered for both anticancer agents; for TMZ the two weekly dose levels considered are 140mg/kg and 210mg/kg; for CPT-11 the two levels are 2.0mg/kg or 3.05mg/kg. Tumor-bearing mice were treated under certain levels of either TMZ, CPT-11 or both. Note that the mice were treated on a one-week or two-week courses per three-week cycle. Table 1 , which became too small to be observable by a reading machine, and had no recurrent growth of tumour in the rest period of the experiment. For this portion of mice, it is believed that they are very likely cured already, see [1] for more details. We also note that a few of the mice had the tumour disappear (< 0.01cm . We are therefore motivated by this dataset to build longitudinal models for repeated measurements of the tumour volume, survival models for time-to-death or sacrifice of the mice, and cure models for the cured mice, simultaneously.
Longitudinal data sub-model
Consider in general the anti-tumour activity of S agents. Suppose that there are n + 1 pre-specified follow-up times t 0 < t 1 < · · · < t n for each of the m subjects/mice. Let Y i (t j ) be the n i -dimensional vector of tumour volumes of the ith mouse measured at the times t 1 , t 2 , · · · , t n i . To make the data normally distributed, we assume that a log scale has been introduced to 
where the random effect
) and the error term ε i = (ε i1 , · · · , ε i,n i ) is assumed to follow the n i -dimensional normal distribution with mean 0 and covariance matrix σ
As pointed out by [1] , however, in the xenograft experiments the tumour born by a immunosuppressants mouse in the control group is expected to grow over the follow-up period. Ignoring this fact can lead to misleading inferences, for example, resulting in underestimates of treatment effects. In order to reflect this fact in the model, ψ is assumed to be such that,
is an increasing function for t > 0.
We use Ψ to denote all possible values of ψ which satisfy this condition.
Proportional hazard and cure sub-models
Let ξ i = 0 denote the ith mouse cured by agents and ξ i = 1 be not cured, eventually. Assume p i = P r(ξ i = 1), the probability of incidence that the The marginal survival function of T i therefore is given by
survival function S i (t) tends to the cure probability (1 − p i ) for large t. As long as the incidence probability p i and the conditional survival function S(t|ξ i = 1), or the conditional hazard function h(t|ξ i = 1), are obtained, the marginal survival function S i (t) can be formed using (4) . In what follows we discuss how to model h(t|ξ i = 1) and p i in terms of covariates of interest.
For simplicity, we assume the censoring mechanism is noninformative and is independent of the longitudinal response Y .
[23] proposed to use the following logistic regression model
to model the incidence probability p i , where z i and λ are covariates and parameters, respectively. They also suggested a parametric survival model for S(t|ξ = 1). [16] generalized the work of [23] to the following Cox proportional hazard model
where w i (t) and α are covariates and parameters, respectively, and h 0 (t|ξ i = 1) is the conditional baseline hazard function.
The models above, however, take no account of the likely relation among the incidence probability, the conditional hazard function and the tumour volume Y . As a result, the separate use of those models may lead to biased statistical inferences. Instead, we propose to use the random effects u i in the longitudinal model (1) , to link the longitudinal and survival-cure models. In other words, we use the following logistic regression model
to model the incidence probability, and use the following proportional hazard frailty model
to model the conditional hazard function, where π 1 in (5) and π 2 in (4) are unknown link parameters. If the estimators of π 1 and π 2 are statistically significant, we conclude that the joint modelling of the longitudinal and survival-cure data is really necessary. Otherwise, the separate modelling strategy may be preferred.
Note that the cure probability in (4) considered here is the probability that the cure event eventually occurs. Therefore it does not depend on time.
In our model the cure probability depends on z i (treatment methods) and u i (the tumor characteristics: baseline u i0 and rate u i1 ). We may consider that the cure rate depends on time (the tumor volumes in time). This can be done using a competing risk model or a Markov transition model to model the hazard rates for death event and cure event. We here consider the simpler model (4), because in our study the cure event time cannot be observed exactly. This is because although mice which had tumor size less than 0.01 at week 12 were treated as cured, but we are not sure when exactly these mice's tumor disappear (due to the tumor size reading machine constraint).
Complete log-likelihood function
Given the random effect u i , we assume the longitudinal data and survivalcure data are independent. It is noted that the incidence ξ i may be observable or unobservable, depending whether or not the censoring occurs. Define ξ = 
and the unobservable data (u, ξ m ), apart from a constant, can be written as
For the baseline hazard function h 0 (t|ξ i = 1), we assume it is a piecewise constant function as well, that is,
where h 0 = (h 01 , · · · , h 0n h ) are unknown parameters.
In our study w i (t) is chosen as the cumulative dose level until time t and it is piecewise constant. Therefore the evaluation for the integration in (6) is straightforward.
Bayesian Inference
We propose to use a Bayesian approach to make statistical inferences for the joint models (1), (4) and (5) We specify independent normal priors for the parameters β, α and λ of which all are assumed to have very large variances. We also specify inverse Gamma priors for the random errors variance σ 2 ε and random effects variance Σ u . We choose a Gamma prior for each h 0j (j = 1, 2, ..., n), so that a conjugate posterior distribution for h 0j is easy to obtain. We assume a normal distribution, N (τ, ς), as the prior for each component of the link parameters π 1 and π 2 .
We propose to use the DIC value to select the most appropriate model. The DIC value consists of two terms, one for goodness-of-fit measured by the deviance evaluated at the posterior mean of parameters, and the other accounting for a penalty defined by twice of the effective number of parameters.
The latter is defined by the mean deviance minus the deviance evaluated at the posterior mean. Under the model assumption with missing data, the DIC is defined by
. See [25] and [26] for more details.
Following the notations in Section 2, we denote n i as the number of repeated measurements for the ith mouse (n i ≤ 12). Let x (1) i,t be the cumulative dose of TMZ and x (2) i,t be the cumulative dose of CPT-11, which are received by the ith mouse till week t, t = 1, ..., n i , i = 1, ..., 51. To account for the synergism of the two drugs, following [1] we take x Among the 51 mice, in total 25 mice died of toxicity or were sacrificed as the tumour volumes were quadrupled. On the other hand, 14 mice were considered to be cured by the end of the experiment, as they survived 12 months and have tumor size smaller than 0.01. The remaining 12 mice were not cured by the end of the experiment but survived longer than 12 week, so that their true lifetimes and cure incidence indicators are not observable. We then use the survival model (5) to model the conditional hazard function h i (t|ξ i = 1, w i (t), u i ), where w i (t) = X i (t−). We also use the model (4) to model the incidence probability P r(ξ i = 1|z i , u i ), where By assuming the normal prior N (0, 100) for π 1 and π 2 , in Table 1 we summarize the posterior means and 95% credit intervals of the parameters in the models for each case above. We also provide the relative DIC values for all the four possible scenarios. In each case, we uses 10,000 iterations of MCMC sampling chains following a 5,000-iteration 'burn-in' period.
[ Table 1 , it turns out that the smallest DIC value is achieved by the model that links all the three sub-models, implying that the joint modelling may be necessary. The TMZ, the CPT-11 treatments and their interaction all have significant negative effects on the tumour growth, implying the treatments work in reducing the tumour growth. For the cure model, we can see that the two treatments and their interaction have no significant effects on the incidence probability. The only significant estimate is for the intercept parameter λ 4 , which is about 3.353, leading to the incidence probability being 97% in the absence of treatments. In other words, without treatments the tumour-beard mice have only 3% chances to be cured. For the survival model, the CPT-11 has a significant positive effect on the survival time, but and TMZ-11 and the interaction of the two treatments are not significant.
For the model that links all the three sub-models, the estimate for linking parameter π 1 = 0.607 is significant. This implies that individual tumor growth is a significant risk factor for survivals. The link parameter π 1 is positive, which shows that the bigger the Rh18 tumour volume the higher the hazard rate of death. For the linking parameter π 2 , the estimate for π 22 are significant, but the estimate for π 21 is not significant. This implies that the gradient u i1 (the rate of individual tumor growth) is a significant risk factor for cure probability. The higher the individual tumor growth rate, the higher death probability (the smaller cure probability).
When only having link for longitudinal and survival sub-models (case 2 in Table 1 ), the link parameter π 1 is not significant anymore, which implies that the tumor growth does not have significant effects on survival. This is not true in realistic. In addition, without having the second link parameter π 2 , the parameter λ 2 becomes significant (cases 2 and 4). The main reason for this is that the random effects are not considered in cases 2 and 4, which distorts the estimation of fixed-effect parameter λ.
When only having linking parameter π 2 (case 3 in Table 1 ), the link parameter π 22 is also significant. Although most results in case 3 are similar as that in case 1, not having the first linking parameter (case 3) has a smaller estimate for α 2 = −0.143 than α 2 = −0.217 in case 1. This means that without the first linking parameter, we could underestimate the effects of the treatment agent CPT-11, which is the only significant risk factor for survivals. For this reason and the DIC values, we suggest that case 1, the full model, is more suitable for the data.
We also considered the models without using intrinsic growth constraint. This implies that without treatment, the tumor will decrease approximately before time 0.2 (week 2 as we use week divided by 10 for the new time scale), and then increase after that. However, this is not correct in practice, since the tumor will surely increase if no treatments are received.
We mimic the real data in Section 4 in the following simulation studies. The covariates X i (t), w i (t) and z i are the same as that in the real data study.
In other words, we have three covariates in the simulation: two treatments TMZ and CPT-11, and their interaction. These covariates are included in both the longitudinal and survival models. We also choose two dose levels for the TMZ 42 mg/kg and the CPT-11 0.61 mg/kg and then consider eight groups of treatments as that in data analysis. The sample size is m = 51 and the number of samples in each group is the same as that in the real data study. Given the random effects u i and covariates z i , the incidence event ξ i is generated from the model (4).
For those subjects with incidence indicator ξ i = 1, on the other hand, the survival model (5) is used to generate the survival outcomes T i . The baseline hazard rate h 0 (t|ξ i = 1) is assumed to be a piecewise constant function
and h 01 = 1.6, h 02 = 3.0, h 03 = 9.8, h 04 = 16.7, which are the estimated values in the real data analysis. It is assumed that the baseline hazard has an increasing jump because the hazard rate increases in the absence of treatments.
Our data are generated from the full model, with linking parameters π 1 = 0.6, π 21 = 0 and π 22 = 1.22.
We compare the simulation results for two models, the model with the association (π 1 = 0 and π 2 = 0) and the model without the association (π 1 = 0, π 2 = 0). We simulate 100 data sets and calculate the sample mean and the sample standard deviation for each parameter estimator. For each data set, we draw 5,000 random samples from the posterior distributions following a 5,000-iteration 'burn-in' period in order to estimate the parameters. Table 2 provides the parameter estimators, standard deviations and coverage probability of credible interval.
When the latent association of longitudinal and survival-cure data does exist, i.e., π 1 = 0 and π 2 = 0, the proposed joint modelling approach performs very well. For example, the link parameter estimators of π 1 and π 22 are statistically significant, which correctly identifies that the joint models are really necessary. On the contrary, the separated modelling approach that ignores the existing inherent association gives estimates with larger bias in the survival models. In addition, the separate model has lower coverage probability.
[ Table 2 Some further research needs to be studied when each mouse has multiple tumours. [21] described an example of preclinical studies evaluating the anti-tumour effects of exemestane and tamoxifen for postmenopausal breast cancer, in which each mouse received subcutaneous injections at two sites and developed four tumours in the process. It is anticipated that multivariate longitudinal responses and multi-dimensional random effects will be involved and additional correlation between tumours for the same mice should be accounted for. We will report this in a follow-up paper.
In our study, the cure probability is just the probability that a mouse is cured or not, eventually. It does not depend on time, which is a limitation of our work. In other studies, it may also be interesting to consider that the cure probability depends on time, if the cure times are available. A Markov transition model might be employed to deal with such problems. 
